Anthropic and OpenEvidence to offer free medical AI to doctors in about 100 countries

Anthropic and OpenEvidence to Offer Free Medical AI to Doctors in About 100 Countries

A tailored version of OpenEvidence’s clinical search tool, powered by Anthropic’s models, is being rolled out across low- and middle-income countries. (September 23, 2026 - 8:52 am)

OpenEvidence, an AI tool used by American doctors, is now accessible in countries with limited access to medical literature, as reported by Reuters. The company partners with Anthropic (find out more) to provide clinicians in these regions with free access to its specialized platform.

This initiative is set to reach approximately 100 countries, including Uganda, Angola, Sudan, Haiti, and Mongolia, according to OpenEvidence. While the financial details remain undisclosed, both companies emphasize their collaboration.

OpenEvidence’s platform answers doctors' clinical questions using peer-reviewed research and treatment guidelines. Currently, it's free for clinicians in the United States and Europe. Anthropic contributes with its backend technology, while OpenEvidence adapts the system to regional healthcare needs.

As stated by founder Daniel Nadler, US clinicians utilized the platform 42 million times in August. This year, OpenEvidence has been working with health organizations in Rwanda and Botswana, tailoring its tools to suit local disease patterns.

Nadler addresses concerns about AI trained primarily on high-income country data:

“One hundred percent of what we are developing for these areas is designed to be context adaptive."

Anthropic's president, Daniela Amodei, agrees that market incentives alone wouldn't have led to this collaboration. She sees this project as a significant step forward.

Clinicians using the tool prioritize access over AI itself. Dr. Ahmed Bendary, a cardiologist from Benha University in Egypt, highlights the importance of expanding the tool beyond the US and Europe, especially where access to major journals is limited.

The primary focus now shifts to adapting a tool predominantly based on evidence from wealthy countries for use in diverse regions like Mongolia and Sudan, one country at a time.

Leave a Reply